Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
21 Results for "
DA neurons
" in MedChemExpress (MCE) Product Catalog:
Products (21)
21 Results for "DA neurons" in MCE Product Catalog:
7
7 Publications Verification
Cat. No.: HY-18705
CAS No.: 932986-18-0
Research Areas:
Azoramide is a potent, orally active small-molecule modulator of the unfolded protein response (UPR). Azoramide improves ER protein folding and elevates ER chaperone capacity, which together protects cells against ER stress. Azoramide alleviates PLA2G6 mutant-induced ER stress through modulating unfolded protein response, and enhances the CERB signaling to rescue mitochondrial function, thereby preventing apoptosis of DA neurons. Azoramide has antidiabetic activity .
1
1 Cited Publications
Target:
Research Areas:
Tipepidine hydrochloride reversibly inhibits dopamine (DA) D2 receptor-mediated GIRK currents (IDA(GIRK)) with an IC50 of 7.0 μM. Tipepidine hydrochloride subsequently activates VTA dopamine neuron . Tipepidine hydrochloride, a non-narcotic antitussive, exerts an antidepressant-like effect .
1
1 Cited Publications
Cat. No.: HY-163987
CAS No.: 3061491-60-6
Target:
Research Areas:
SIRT3 activator 2 (compound 2a) is a SIRT3 activator. SIRT3 activator 2 improved the thermal stability of SIRT3 in SH-SY5Y cells, indicating that it can directly bind to SIRT3, has SIRT3 dependency in SH-SY5Y to clear α-Syn. SIRT3 activator 2 improves motor function in Parkinson mice, preventing Parkinson (DA) neuron loss in the substantia nigra in a dose-dependent manner .
Research Areas:
GRK2 Inhibitor 1 (methyl 5-[2-(5-nitro-2-furyl)vinyl]-2-furoate) is a dual GRK2/β-ARK1 inhibitor that induces dopamine (DA) inhibition reversal (DIR). GRK2 Inhibitor 1 can also block serotonin-induced or neurotensin-induced DIR reversal. Note: DIR refers to the phenomenon in which neurons in addiction-related brain pathways become less sensitive to DA inhibition when exposed to moderate concentrations of DA for a long time .
Target:
Research Areas:
(±)-Salsolinol hydrochloride is the hydrochloride form of (±)-Salsolinol (HY-113316). (±)-Salsolinol hydrochloride is a Dopamine (HY-B0451)-derived endogenous metabolite. (±)-Salsolinol hydrochloride activates μ-opioid receptors (MORs), reduces GABAergic transmission, increases the excitability of dopamine (DA) neurons, and thus accelerates the sustained firing of neurons in the posterior ventral tegmental area (pVTA) .
Target:
Research Areas:
Tipepidine reversibly inhibits dopamine (DA) D2 receptor-mediated GIRK currents (IDA(GIRK)) with an IC50 of 7.0 μM. Tipepidine subsequently activates VTA dopamine neuron . Tipepidine, a non-narcotic antitussive, exerts an antidepressant-like effect .
Cat. No.: HY-118706
CAS No.: 108351-90-2
Target:
Research Areas:
PD 118440 is an orally active dopamine (DA) agonist. PD 118440 has significant central nervous system effects, including inhibition of striatal DA synthesis, suppression of DA neuron firing, and reversal of Reserpine (HY-N0480)-induced depression in rats .
Cat. No.: HY-138806
CAS No.: 943902-10-1
Target:
Research Areas:
PAQ (Compound 4c) is a quinoxaline derivative. PAQ is an orally active neuroprotective agent, which targets dopamine (DA) neurons and activates reticulum endoplasmic ryanodine receptor (RyR) channels, without effects on glia cells .
Cat. No.: HY-W013353
CAS No.: 59709-57-8
Target:
Research Areas:
(RS)-Salsolinol hydrobromide is the hydrobromide form of (±)-Salsolinol (HY-113316). (RS)-Salsolinol hydrobromide is a Dopamine (HY-B0451)-derived endogenous metabolite. (RS)-Salsolinol hydrobromide activates μ-opioid receptors (MORs), reduces GABAergic transmission, increases the excitability of dopamine (DA) neurons, and thus accelerates the sustained firing of neurons in the posterior ventral tegmental area (pVTA) .
Cat. No.: HY-187242
Target:
Research Areas:
DMG-PEG1000-RVG29 is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 1000 Da, and RVG29 peptide (YTIWMPENPRPGTPCDIFTNSRGKRASNG) (HY-P5623) as the terminal targeting/functional ligand. DMG-PEG1000-RVG29 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against the nAChR α7 subunit on neurons and brain endothelial cells.
Cat. No.: HY-187242A
Target:
Research Areas:
DMG-PEG2000-RVG29 is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and RVG29 peptide (YTIWMPENPRPGTPCDIFTNSRGKRASNG) (HY-P5623) as the terminal targeting/functional ligand. DMG-PEG2000-RVG29 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against the nAChR α7 subunit on neurons and brain endothelial cells.
Cat. No.: HY-187242B
Target:
Research Areas:
DMG-PEG3400-RVG29 is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 3400 Da, and RVG29 peptide (YTIWMPENPRPGTPCDIFTNSRGKRASNG) (HY-P5623) as the terminal targeting/functional ligand. DMG-PEG3400-RVG29 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against the nAChR α7 subunit on neurons and brain endothelial cells.
Cat. No.: HY-187242C
Target:
Research Areas:
DMG-PEG5000-RVG29 is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 5000 Da, and RVG29 peptide (YTIWMPENPRPGTPCDIFTNSRGKRASNG) (HY-P5623) as the terminal targeting/functional ligand. DMG-PEG5000-RVG29 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against the nAChR α7 subunit on neurons and brain endothelial cells.
Cat. No.: HY-187278
Target:
Research Areas:
DOPE-PEG1000-RVG29 is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 1000 Da, and RVG29 peptide (YTIWMPENPRPGTPCDIFTNSRGKRASNG) (HY-P5623) as the terminal targeting/functional ligand. DOPE-PEG1000-RVG29 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against the nAChR α7 subunit on neurons and brain endothelial cells.
Cat. No.: HY-187278A
Target:
Research Areas:
DOPE-PEG2000-RVG29 is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and RVG29 peptide (YTIWMPENPRPGTPCDIFTNSRGKRASNG) (HY-P5623) as the terminal targeting/functional ligand. DOPE-PEG2000-RVG29 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against the nAChR α7 subunit on neurons and brain endothelial cells.
Cat. No.: HY-187278B
Target:
Research Areas:
DOPE-PEG3400-RVG29 is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 3400 Da, and RVG29 peptide (YTIWMPENPRPGTPCDIFTNSRGKRASNG) (HY-P5623) as the terminal targeting/functional ligand. DOPE-PEG3400-RVG29 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against the nAChR α7 subunit on neurons and brain endothelial cells.
Cat. No.: HY-187278C
Target:
Research Areas:
DOPE-PEG5000-RVG29 is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 5000 Da, and RVG29 peptide (YTIWMPENPRPGTPCDIFTNSRGKRASNG) (HY-P5623) as the terminal targeting/functional ligand. DOPE-PEG5000-RVG29 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against the nAChR α7 subunit on neurons and brain endothelial cells.
Cat. No.: HY-187314A
Target:
Research Areas:
DPPE-PEG2000-RVG29 is a functionalized PEGylated lipid conjugate composed of three modular components: dipalmitoylphosphatidylethanolamine (DPPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and RVG29 peptide (YTIWMPENPRPGTPCDIFTNSRGKRASNG) (HY-P5623) as the terminal targeting/functional ligand. DPPE-PEG2000-RVG29 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against the nAChR α7 subunit on neurons and brain endothelial cells.
Cat. No.: HY-187322A
Target:
Research Areas:
DSG-PEG2000-RVG29 is a functionalized PEGylated lipid conjugate composed of three modular components: distearoylglycerol (DSG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and RVG29 peptide (YTIWMPENPRPGTPCDIFTNSRGKRASNG) (HY-P5623) as the terminal targeting/functional ligand. DSG-PEG2000-RVG29 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against the nAChR α7 subunit on neurons and brain endothelial cells.
Cat. No.: HY-L085
2,232 compounds
Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.
MCE offers a unique collection of 2,232 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
